These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38779416)

  • 1. Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions.
    Sekar AP; Nurmala S; Matsuura E; Tan XW; Rahmasari R; Sauriasari R
    Breast Cancer (Auckl); 2024; 18():11782234241240173. PubMed ID: 38779416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
    Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
    Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
    Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells.
    Vaziri-Gohar A; Zheng Y; Houston KD
    Mol Cancer Res; 2017 Apr; 15(4):489-497. PubMed ID: 28096479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin Restores the Drug Sensitivity of MCF-7 Cells Resistant Derivates via the Cooperative Modulation of Growth and Apoptotic-Related Pathways.
    Sorokin D; Shchegolev Y; Scherbakov A; Ryabaya O; Gudkova M; Berstein L; Krasil'nikov M
    Pharmaceuticals (Basel); 2020 Aug; 13(9):. PubMed ID: 32825760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.
    Chen J; Hou R; Zhang X; Ye Y; Wang Y; Tian J
    PLoS One; 2014; 9(3):e91245. PubMed ID: 24618835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
    Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
    J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells.
    Peng J; Jordan VC
    Int J Oncol; 2010 Feb; 36(2):451-8. PubMed ID: 20043081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
    Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention.
    Zordoky BN; Bark D; Soltys CL; Sung MM; Dyck JR
    Biochim Biophys Acta; 2014 Jun; 1840(6):1943-57. PubMed ID: 24462945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
    Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
    BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
    Phoenix KN; Vumbaca F; Claffey KP
    Breast Cancer Res Treat; 2009 Jan; 113(1):101-11. PubMed ID: 18256928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
    Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
    Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
    Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.
    Tohkayomatee R; Reabroi S; Tungmunnithum D; Parichatikanond W; Pinthong D
    Molecules; 2022 May; 27(11):. PubMed ID: 35684480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.